Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Suppliers that maintain consistent quality and proper research-use positioning
Comprehensive List of FDA-approved GLP-1 Receptor Agonists (as of mid-2025)Jun 14, 20252 min read All Available GLP-1 Receptor AgonistsBrand NameGeneric NameManufacturerOzempicSemaglutideNovo NordiskWegovySemaglutide (higher dose)Novo NordiskRybelsusSemaglutide (oral)Novo NordiskMounjaroTirzepatide (dual GLP-1/GIP)Eli LillyZepboundTirzepatide (weight loss)Eli LillyVictozaLiraglutideNovo NordiskSaxendaLiraglutide (higher dose for weight loss)Novo NordiskByettaExenatideAstraZenecaBydureon BCiseExenatide ERAstraZenecaAdlyxinLixisenatideSanofiTrulicityDulaglutideEli LillyEperzan / Tanzeum (withdrawn but notable)AlbiglutideGSK (discontinued) GLP-1 Comparison ChartNameBenefitsSide EffectsStudy LinksSemaglutide (Ozempic, Wegovy, Rybelsus)- Significant weight loss (up to 15%) - Lowers A1C ~1.5% - Cardiovascular protection (Ozempic) - Once-weekly (injection) or daily (oral)- Nausea - Vomiting - Diarrhea - Constipation - Risk of pancreatitisSTEP Trials (Wegovy) SUSTAIN Trials (Ozempic)Tirzepatide (Mounjaro, Zepbound)- Weight loss up to 20% - Superior A1C reduction (~2%+) - Combines GLP-1 + GIP effects - Weekly injection- GI upset - Fatigue - Constipation - Gallbladder issues (rare)SURMOUNT Trials (Zepbound) SURPASS Trials (Mounjaro)Liraglutide (Victoza, Saxenda)- A1C reduction ~1-1.5% - Weight loss up to 8% - Cardiovascular benefit (Victoza) - Daily injection- Nausea - Headache - Injection site irritation - Possible pancreatitisLEADER Trial (Victoza) SCALE Trial (Saxenda)Exenatide (Byetta, Bydureon)- A1C reduction ~1% - Weight neutral or mild loss - Twice-daily or weekly injection- Nausea - Hypoglycemia (esp
A pharmaceutical composition for intranasal administration, comprising an active ingredient and essential excipients, said active ingredient comprising 0.01% to 20% by weight (w/v) of semaglutide, or a pharmaceutically acceptable salt thereof, said pharmaceutical composition further comprising one or more permeation enhancers selected from a group consisting of cell penetrating peptides, tight junction modulating agents, and bioadhesive agents
However, in special circumstances such as weather conditions or other unforeseen delays, this timeframe may vary
